Cargando…

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort

Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therap...

Descripción completa

Detalles Bibliográficos
Autores principales: VAN MUIJEN, Marloes. E., THOMAS, Sarah E., GROENEWOUD, Hans M. M., OTERO, Marisol E., OSSENKOPPELE, Paul M., NJOO, Marcellus D., DODEMONT, Sharon R. P., KOP, Else N., BERENDS, Maartje A. M., KOETSIER, Marjolein I. A., MOMMERS, Johannes M., KÖRVER, John E. M., TUPKER, Ron A., DE BRUIN-WELLER, Marjolein S., WEPPNER-PARREN, Lizelotte J. M. T., PETERS, Bas, KLEINPENNING, Marloes M., KUIJPERS, Astrid L. A., ARNOLD, W. Peter, VAN LÜMIG, Paula P. M., VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574692/
https://www.ncbi.nlm.nih.gov/pubmed/35356990
http://dx.doi.org/10.2340/actadv.v102.206
_version_ 1784811156445069312
author VAN MUIJEN, Marloes. E.
THOMAS, Sarah E.
GROENEWOUD, Hans M. M.
OTERO, Marisol E.
OSSENKOPPELE, Paul M.
NJOO, Marcellus D.
DODEMONT, Sharon R. P.
KOP, Else N.
BERENDS, Maartje A. M.
KOETSIER, Marjolein I. A.
MOMMERS, Johannes M.
KÖRVER, John E. M.
TUPKER, Ron A.
DE BRUIN-WELLER, Marjolein S.
WEPPNER-PARREN, Lizelotte J. M. T.
PETERS, Bas
KLEINPENNING, Marloes M.
KUIJPERS, Astrid L. A.
ARNOLD, W. Peter
VAN LÜMIG, Paula P. M.
VAN DEN REEK, Juul M. P. A.
DE JONG, Elke M. G. J.
author_facet VAN MUIJEN, Marloes. E.
THOMAS, Sarah E.
GROENEWOUD, Hans M. M.
OTERO, Marisol E.
OSSENKOPPELE, Paul M.
NJOO, Marcellus D.
DODEMONT, Sharon R. P.
KOP, Else N.
BERENDS, Maartje A. M.
KOETSIER, Marjolein I. A.
MOMMERS, Johannes M.
KÖRVER, John E. M.
TUPKER, Ron A.
DE BRUIN-WELLER, Marjolein S.
WEPPNER-PARREN, Lizelotte J. M. T.
PETERS, Bas
KLEINPENNING, Marloes M.
KUIJPERS, Astrid L. A.
ARNOLD, W. Peter
VAN LÜMIG, Paula P. M.
VAN DEN REEK, Juul M. P. A.
DE JONG, Elke M. G. J.
author_sort VAN MUIJEN, Marloes. E.
collection PubMed
description Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study.
format Online
Article
Text
id pubmed-9574692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Society for Publication of Acta Dermato-Venereologica
record_format MEDLINE/PubMed
spelling pubmed-95746922022-10-20 Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort VAN MUIJEN, Marloes. E. THOMAS, Sarah E. GROENEWOUD, Hans M. M. OTERO, Marisol E. OSSENKOPPELE, Paul M. NJOO, Marcellus D. DODEMONT, Sharon R. P. KOP, Else N. BERENDS, Maartje A. M. KOETSIER, Marjolein I. A. MOMMERS, Johannes M. KÖRVER, John E. M. TUPKER, Ron A. DE BRUIN-WELLER, Marjolein S. WEPPNER-PARREN, Lizelotte J. M. T. PETERS, Bas KLEINPENNING, Marloes M. KUIJPERS, Astrid L. A. ARNOLD, W. Peter VAN LÜMIG, Paula P. M. VAN DEN REEK, Juul M. P. A. DE JONG, Elke M. G. J. Acta Derm Venereol Original Article Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study. Society for Publication of Acta Dermato-Venereologica 2022-05-16 /pmc/articles/PMC9574692/ /pubmed/35356990 http://dx.doi.org/10.2340/actadv.v102.206 Text en © 2022 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license
spellingShingle Original Article
VAN MUIJEN, Marloes. E.
THOMAS, Sarah E.
GROENEWOUD, Hans M. M.
OTERO, Marisol E.
OSSENKOPPELE, Paul M.
NJOO, Marcellus D.
DODEMONT, Sharon R. P.
KOP, Else N.
BERENDS, Maartje A. M.
KOETSIER, Marjolein I. A.
MOMMERS, Johannes M.
KÖRVER, John E. M.
TUPKER, Ron A.
DE BRUIN-WELLER, Marjolein S.
WEPPNER-PARREN, Lizelotte J. M. T.
PETERS, Bas
KLEINPENNING, Marloes M.
KUIJPERS, Astrid L. A.
ARNOLD, W. Peter
VAN LÜMIG, Paula P. M.
VAN DEN REEK, Juul M. P. A.
DE JONG, Elke M. G. J.
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
title Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
title_full Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
title_fullStr Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
title_full_unstemmed Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
title_short Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
title_sort direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574692/
https://www.ncbi.nlm.nih.gov/pubmed/35356990
http://dx.doi.org/10.2340/actadv.v102.206
work_keys_str_mv AT vanmuijenmarloese directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT thomassarahe directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT groenewoudhansmm directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT oteromarisole directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT ossenkoppelepaulm directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT njoomarcellusd directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT dodemontsharonrp directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT kopelsen directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT berendsmaartjeam directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT koetsiermarjoleinia directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT mommersjohannesm directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT korverjohnem directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT tupkerrona directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT debruinwellermarjoleins directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT weppnerparrenlizelottejmt directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT petersbas directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT kleinpenningmarloesm directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT kuijpersastridla directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT arnoldwpeter directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT vanlumigpaulapm directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT vandenreekjuulmpa directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort
AT dejongelkemgj directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort